406 related articles for article (PubMed ID: 24203647)
1. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
2. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
[TBL] [Abstract][Full Text] [Related]
3. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
Webb MI; Walsby CJ
Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
[TBL] [Abstract][Full Text] [Related]
4. Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.
Cetinbas N; Webb MI; Dubland JA; Walsby CJ
J Biol Inorg Chem; 2010 Feb; 15(2):131-45. PubMed ID: 19707803
[TBL] [Abstract][Full Text] [Related]
5. Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin.
Webb MI; Chard RA; Al-Jobory YM; Jones MR; Wong EW; Walsby CJ
Inorg Chem; 2012 Jan; 51(2):954-66. PubMed ID: 22224431
[TBL] [Abstract][Full Text] [Related]
6. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
Webb MI; Walsby CJ
Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
[TBL] [Abstract][Full Text] [Related]
7. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
Mu C; Chang SW; Prosser KE; Leung AW; Santacruz S; Jang T; Thompson JR; Yapp DT; Warren JJ; Bally MB; Beischlag TV; Walsby CJ
Inorg Chem; 2016 Jan; 55(1):177-90. PubMed ID: 26652771
[TBL] [Abstract][Full Text] [Related]
8. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the binding of cis/trans-[MCl4(1H-indazole)(NO)](-) (M = Ru, Os) complexes to human serum albumin.
Dömötör O; Rathgeb A; Kuhn PS; Popović-Bijelić A; Bačić G; Enyedy EA; Arion VB
J Inorg Biochem; 2016 Jun; 159():37-44. PubMed ID: 26908285
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
[TBL] [Abstract][Full Text] [Related]
11. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
[TBL] [Abstract][Full Text] [Related]
12. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
[TBL] [Abstract][Full Text] [Related]
13. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
Bijelic A; Theiner S; Keppler BK; Rompel A
J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
[TBL] [Abstract][Full Text] [Related]
14. Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies.
Nagy EM; Nardon C; Giovagnini L; Marchiò L; Trevisan A; Fregona D
Dalton Trans; 2011 Nov; 40(44):11885-95. PubMed ID: 21971872
[TBL] [Abstract][Full Text] [Related]
15. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
[TBL] [Abstract][Full Text] [Related]
16. Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.
Webb MI; Walsby CJ
Dalton Trans; 2015 Oct; 44(40):17482-93. PubMed ID: 26174110
[TBL] [Abstract][Full Text] [Related]
17. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
18. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in ruthenium anticancer drugs.
Levina A; Mitra A; Lay PA
Metallomics; 2009 Nov; 1(6):458-70. PubMed ID: 21305154
[TBL] [Abstract][Full Text] [Related]
20. Tuning the cytotoxic properties of new ruthenium(III) and ruthenium(II) complexes with a modified bis(arylimino)pyridine Schiff base ligand using bidentate pyridine-based ligands.
Garza-Ortiz A; Maheswari PU; Lutz M; Siegler MA; Reedijk J
J Biol Inorg Chem; 2014 Jun; 19(4-5):675-89. PubMed ID: 24430199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
